ArticleMolecules (Basel, Switzerland)2018
Synthesis of New 1,3,5-Triazine-Based 2-Pyrazolines as Potential Anticancer Agents.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- 3,5-Disubstituted pyrazoline as a promising core for anticancer agents: mechanisms of action and therapeutic potentials.Future medicinal chemistry · 2025Review
- A Pharmacological Overview and Recent Patent of Triazine Scaffold in Drug Development: A Review.Current organic synthesis · 2025Review
- Synthesis of Novel Triazine-Based Chalcones and 8,9-dihydro-7International journal of molecular sciences · 2024Article
- 1,3,5-Triazine: Recent Development in Synthesis of its Analogs and Biological Profile.Mini reviews in medicinal chemistry · 2024Review
- Review
- Synthetic Approaches, Biological Activities, and Structure-Activity Relationship of Pyrazolines and Related Derivatives.Topics in current chemistry (Cham) · 2023Review
- Multicomponent Molecular Systems Based on Porphyrins, 1,3,5-Triazine and Carboranes: Synthesis and Characterization.Molecules (Basel, Switzerland) · 2022Article
- Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)-ACS omega · 2022Article
- Recent Advances in the Biological Activity of s-Triazine Core Compounds.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors.Frontiers in chemistry · 2022Article
- Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors.International journal of molecular sciences · 2021Article
- Biguanide-Based Synthesis of 1,3,5-Triazine Derivatives with Anticancer Activity and 1,3,5-Triazine Incorporated Calcium Citrate Nanoparticles.Molecules (Basel, Switzerland) · 2021Article
- Triazine Derivative as Putative Candidate for the Reduction of Hormone-Positive Breast Tumor:Frontiers in pharmacology · 2021Article
- Synthesis, biological evaluation, andRSC advances · 2020Article
- Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new series of 1,3,5-triazine-containing 2-pyrazoline derivatives (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.